ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma.
Yiwen Lv, Shuang Liu, Hong Wu, Guiluan Li, Ying Rong, Guangchao Li, Yangmin Zhu, Qi Zhong, Ruiming Ou, Huijuan Shen and 7 more
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Hong WuThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Guiluan LiThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Ying RongThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Guangchao LiThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Yangmin ZhuThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Qi ZhongThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Ruiming OuThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Huijuan ShenThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Zhi LiuThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Zhenwei WangThe Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Pei LinGuangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, People's Republic of China.ORCID https://orcid.org/0000-0002-1455-1888 Funding
Foundation of Guangdong Second Provincial General Hospital 2024C001Foundation of Guangdong Second Provincial General Hospital 2024E006Foundation of Guangdong Second Provincial General Hospital TJGC-2023005Foundation of Guangdong Second Provincial General Hospital TJGC-2025009Foundation of Guangdong Second Provincial General Hospital TJGC-2026004Foundation of Guangdong Second Provincial General Hospital YN2023-001Foundation of Guangdong Second Provincial General Hospital YY2024-004Foundation of Guangdong Second Provincial General Hospital YY2024-012Foundation of Guangdong Second Provincial General Hospital YY2025-007Guangdong Basic and Applied Basic Research Foundation 2026A1515011519Guangdong Medical Science and Technology Research B2024119Guangzhou Science and Technology Plan Project 2025A03J4290Guangzhou Science and Technology Plan Project 2025A03J4292Guangzhou Science and Technology Plan Project 2025A03J4451Traditional Chinese Medicine of Guangdong Province 20241009Traditional Chinese Medicine of Guangdong Province 20252001
6 · The paper itselfAbstract
Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM). Here, a carrier-free, supramolecular nanoplatform was engineered through the spontaneous co-assembly of two natural alkaloids, berberine (BBR) and nitidine chloride (NC), termed BBR/NC-SAPs, to counter this malignancy. Driven by cooperative π-π stacking and van der Waals forces, BBR/NC-SAPs display superior anti-MM efficacy and optimized biosafety as compared to the free-drug combination. Quantitative proteomics and functional landscapes showed that BBR/NC-SAPs robustly activate iron-dependent ferroptosis, as evidenced by massive lipid peroxidation, intracellular Fe
Indexed as
bortezomib resistancecarrier‐free self‐assemblyferroptosismultiple myelomanatural products
Identifiers
PMID42610639
PMCPMC13483133
What OpenQuestion holds
Textmetadata
Read underepoch 390